Australia markets closed

Chimerix, Inc. (CMRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.2200-0.0300 (-2.40%)
At close: 04:00PM EDT
1.2500 +0.03 (+2.46%)
After hours: 06:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2500
Open1.2400
Bid1.2200 x 1100
Ask1.2300 x 2900
Day's range1.2000 - 1.2500
52-week range1.2000 - 5.3900
Volume653,020
Avg. volume746,768
Market cap107.694M
Beta (5Y monthly)1.18
PE ratio (TTM)0.69
EPS (TTM)1.7700
Earnings date15 May 2023 - 19 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.33
  • GlobeNewswire

    Chimerix Reports Fourth Quarter and Year End 2022 Financial Results and Provides Operational Update

    - Continued Execution and Progress Towards Commercial Approval of Dordaviprone (ONC201) with Global Launch of Phase 3 ACTION Study – – Confirmed Response in Non-H3 K27M Recurrent Glioblastoma Patient During ONC206 Dose Escalation – – Strong Balance Sheet with $266 Million in Cash at Year-End and No Debt – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., March 02, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaning

  • GlobeNewswire

    Chimerix to Present at Cowen and Company 43rd Annual Health Care Conference

    DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 2:10 p.m. ET. An audio webcast of the panel discussion will be available on the Inve

  • GlobeNewswire

    Chimerix to Report Fourth Quarter and Year End 2022 Financial Results and Provide an Operational Update on March 2, 2023

    DURHAM, N.C., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 2, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full-year ended December 31, 2022, and to provide a business overview. To access the live conference call,